RAC 0.81% $1.22 race oncology ltd

Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and...

  1. 262 Posts.
    lightbulb Created with Sketch. 397
    Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy
    https://pubmed.ncbi.nlm.nih.gov/38646672/

    Conclusions: Activation of CDK7 is necessary for DOX-induced cardiomyocyte apoptosis and cardiomyopathy. Our findings uncover a novel proapoptotic role for CDK7 in cardiomyocytes. Moreover, this study suggests that inhibition of CDK7 attenuates DOX-induced cardiotoxicity, but augments the anticancer efficacy of DOX. Therefore, combined administration of CDK7 inhibitor and DOX may exhibit diminished cardiotoxicity but superior anticancer activity.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.22
Change
-0.010(0.81%)
Mkt cap ! $202.7M
Open High Low Value Volume
$1.26 $1.26 $1.14 $381.6K 320.3K

Buyers (Bids)

No. Vol. Price($)
1 7000 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.22 2171 1
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
$1.17
  Change
-0.010 ( 5.54 %)
Open High Low Volume
$1.23 $1.23 $1.14 48407
Last updated 15.52pm 03/05/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.